A phase 1 study of subcutaneous formulation of ALXN1210 with ENHANZE

Trial Profile

A phase 1 study of subcutaneous formulation of ALXN1210 with ENHANZE

Planning
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Haemolytic uraemic syndrome; Immunological disorders; Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Feb 2018 New trial record
    • 20 Feb 2018 According to a Halozyme Therapeutics media release, Roche is planning to initiate this phase 1 study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top